Bone Mineral Density - malecare.org

On the Horizon – Estrogen Receptor Modulator Reduces Bone Complications from Androgen Deprivation Therapy for Prostate Cancer

A multi-center Phase III study discussed at the 2009 meeting of the American Urological Association,[1] has demonstrated that the risk for bone fractures in men on androgen deprivation therapy (ADT) can be reduced by using toremifene (Acapodene). Men, fighting advanced prostate cancer, often receive long-term ADT, which along with other side effects will increase their [...]

By Malecare|2017-10-19T10:54:30-04:00September 26th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Hormone Therapy, On The Horizon, Research, Uncategorized, Understanding APC|2 Comments

On the Horizon – Estrogen Receptor Modulator Reduces Bone Complications from Androgen Deprivation Therapy for Prostate Cancer

A multi-center Phase III study was discussed at the 2009 meeting of the American Urological Association.[1] The perliminar results of this study has demonstrated that the risk for incurring bone fractures in men on androgen deprivation therapy (ADT) is reduced when the drug toremifene (Acapodene) is administered. Men, fighting advanced prostate cancer, often receive long-term [...]

By Malecare|2017-10-19T10:54:32-04:00September 22nd, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Hormone Therapy, On The Horizon, Uncategorized|0 Comments

Combining Radiopharmaceuticals and Bisphosphonates to Treat Bone Mets

A recent study of one man at the Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, The Netherlands combined both treatment modalities, radiopharmaceuticals and bisphosphonates, to combat bone pain caused by bone metastases. Their results were surprising. Bone-seeking radiopharmaceuticals and bisphosphonates are both an indicated treatment for men with prostate cancer when painful [...]

By Malecare|2017-10-19T10:54:41-04:00August 15th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, Metastases, On The Horizon, Uncategorized, Understanding APC|0 Comments

Extending Survival of Prostate Cancer Survivors by Using Sodium Clodronate

In a small trial using oral sodium clodronate, a bisphosphonate like Zometa and Fosamax, it was shown to extended prostate cancer survival by 23 percent (23%). The survival benefit was seen only when the drug was used in combination with hormone therapy in men with metastatic disease. Many doctors have believed that bisphosphonates could have [...]

By Malecare|2017-10-19T10:54:42-04:00August 13th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Metastases, Research, Uncategorized, Understanding APC|0 Comments

On the Horizon – Denosumab, An alternative To Zometa To Protect Bones While Treating Advanced Prostate Cancer

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events Amgen (NASDAQ: AMGN) has announced positive results from a Phase III head-to-head trial evaluating denosumab administered subcutaneously, versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion. Currently Zometa is the FDA approved treatment for bone [...]

By Malecare|2017-10-19T10:54:43-04:00August 9th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Metastases, On The Horizon, Uncategorized, Understanding APC|0 Comments